News
Vantia Therapeutics announces £4 million fund raising
6 July 2011
Vantia Therapeutics raises £4 million to fund clinical development of lead compounds.
Vantia appoints new CEO
9 June 2010
Vantia Therapeutics announces that it has appointed Andrew Crockett to the position of Chief Executive Officer.
Vantia Therapeutics is an emerging pharmaceutical company developing novel small molecule drugs targeting large areas of unmet medical need.
Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, product candidates that target conditions affecting millions of people, are poorly treated and represent billion dollar markets.
Vantia Therapeutics' strategy is to develop its proprietary drug candidates through Phase II clinical testing and commercialise them through partnerships.
The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
